Ayala Pharmaceuticals, Inc.
ADXSOTCHealthcare
$0.60
+$0.00(+0.00%)
Market Cap$25707577
P/E Ratio—
52W High$0.801
52W Low$0.0011
Ayala Pharmaceuticals, Inc. (ADXS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ADXS · as of 2026-06-15
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-10 | 2020-10 | 2019-10 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.01M | $0.25M | $3.24M | $0.25M | $2.33M |
| Cost of Revenue | $0.01M | $0.31M | $3.71M | $1.28M | $1.28M |
| Gross Profit | $0.00M | ($0.06M) | ($0.47M) | ($1.03M) | $1.05M |
| Gross Margin %(computed) | 0.00% | -25.60% | -14.44% | -407.91% | 44.94% |
| Operating Expenses | |||||
| R&D Expenses | $24.08M | $7.61M | $10.56M | $15.61M | $14.42M |
| G&A Expenses | $12.19M | $9.74M | $11.46M | $11.09M | $4.34M |
| Total Operating Expenses | $36.27M | $16.03M | $22.03M | $26.70M | $18.76M |
| Operating Income | ($36.27M) | ($16.09M) | ($18.79M) | ($26.45M) | ($17.71M) |
| Operating Margin %(computed) | — | — | -579.81% | — | -758.83% |
| Interest Income | $0.03M | $0.07M | $0.01M | $0.11M | $0.23M |
| Interest Expense | $15.75M | $0.00M | $0.26M | $0.00M | $0.00M |
| Income Before Tax | ($51.98M) | ($14.31M) | ($17.81M) | ($26.42M) | ($17.49M) |
| Income Tax Expense | ($3.91M) | $0.05M | $0.05M | $0.05M | $0.31M |
| Net Income | ($48.07M) | ($14.36M) | ($17.86M) | ($26.47M) | ($17.79M) |
| Net Margin %(computed) | — | — | -551.30% | — | -762.30% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-7.99 | $-7.90 | $-11.07 | $-34.71 | $-93.60 |
| Wtd Avg Shares | 6.02M | 1.82M | 1.61M | 0.76M | 0.19M |
| EBITDA | ($35.87M) | ($15.78M) | ($18.77M) | ($24.39M) | ($17.56M) |
| EBITDA Margin %(computed) | — | — | -579.20% | — | -752.40% |
Data source: Financial Modeling Prep · Last updated: 2026-06-15 · USD · M
Explore more Ayala Pharmaceuticals, Inc. data
About Ayala Pharmaceuticals, Inc. (ADXS) Income Statement
Ayala Pharmaceuticals, Inc. (ADXS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, ADXS reported revenue of $0.00B, gross profit of $0.00B (gross margin 0.00%), and net income of ($0.05B) — a net profit margin of -369784.62%.
Frequently asked questions
ADXS · 4 questionsAyala Pharmaceuticals, Inc. (ADXS) reported revenue of $0.00B for 2023, down 94.8% year-over-year.
ADXS revenueADXS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15